Scientific Publications
2Nov, 2017
Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease Over 130 Weeks: Results of Phase 3 Extension Study
S. Abushakra, MD, A. Porsteinsson, MD, C. Sadowsky, MD, B. Vellas, MD, S. [...]
23Oct, 2017
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
John A. Hey, Jeremy Y. Yu, Mark Versavel, Susan Abushakra, Petr Kocis, Aidan [...]
17Jul, 2017
ALZ-801 Mechanism of Action: Stoichiometry of Beta Amyloid Anti-Oligomer Effect, PK/PD, and Clinical Dose Selection for Confirmatory Phase 3 Program in Alzheimer’s Disease
J.A. Hey, P. Kocis, S. Abushakra, J. Yu , A. Power, K. Blennow, [...]
22Jun, 2017
Clinical Effects Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease Suggest Disease Modification Potential
S. Abushakra, A. Porsteinsson, P. Scheltens, C. Sadowsky, B. Vellas, J. Cummings, S. [...]
24Apr, 2017
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data
Petr Kocis, Martin Tolar, Jeremy Yu, William Sinko, Soumya Ray, Kaj Blennow, Howard Fillit, John A. Hey Abstract Background Amyloid beta (Aβ) oligomers play a critical role in the [...]
29Mar, 2017
ALZ-801 Brain Penetration, PK/PD Analyses And Clinical Dose Projection Form The Basis For Confirmatory Phase 3 Study In Alzheimer’s Disease
Abstract OBJECTIVES: ALZ-801 is a novel prodrug of tramiprosate with improved pharmacokinetics (PK) [...]